申请人:WARNER-LAMBERT COMPANY
公开号:EP0125749A2
公开(公告)日:1984-11-21
4,5-Dihydro-6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones 6-[(substituted)-lH-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones and pharmaceutically acceptable acid addition salts thereof are useful as cardiotonic and antihypertensive agents.
The above compounds cause a significant increase in myocardial contractility in the dog and also cause a decrease in blood pressure in the spontaneously hypertensive rat. The compounds are produced by reacting the appropriate y-oxo-imidazolebutanoic acid with a suitably substituted hydrazine to provide 4,5-dihydro -6- (substituted) imidazolyl -3(2H)- pyridazinones which are oxidized to 6- (substituted)imidazolyl -3(2H)- pyridazinones.
4,5-二氢-6-[(取代的)-1H-咪唑-4-基或 5-基]-3(2H)-哒嗪酮 6-[(取代的)-lH-咪唑-4-基或 5-基]-3(2H)-哒嗪酮及其药学上可接受的酸加成盐可用作强心剂和降压药。
上述化合物能显著增强狗的心肌收缩力,还能降低自发性高血压大鼠的血压。这些化合物是由适当的 y-氧代咪唑丁酸与适当取代的肼反应生成 4,5-二氢-6-(取代的)咪唑基-3(2H)-哒嗪酮,后者被氧化成 6-(取代的)咪唑基-3(2H)-哒嗪酮。